Lexiscan Related Published Studies
Well-designed clinical trials related to Lexiscan (Regadenoson)
Attenuation of the side effect profile of regadenoson: a randomized double-blind
placebo-controlled study with aminophylline in patients undergoing myocardial
perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial. [2013]
A randomized, double-blind, placebo-controlled study assessing the safety and
tolerability of regadenoson in subjects with asthma or chronic obstructive
pulmonary disease. [2012]
Attenuation of the side effect profile of regadenoson: a randomized
double-blinded placebo-controlled study with aminophylline in patients undergoing
myocardial perfusion imaging. "The ASSUAGE trial". [2012]
Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study. [2011.02]
Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. [2009.04]
The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. [2009.01]
Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. [2008.05]
Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). [2008.05]
Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. [2008.05]
Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. [2007.09]
A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. [2006]
Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. [2005.12.06]
Other research related to Lexiscan (Regadenoson)
Rapid detection of coronary artery stenoses with real-time perfusion echocardiography during regadenoson stress. [2011.11.01]
Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging. [2011.08]
Safety of regadenoson in patients with end-stage liver disease. [2011.02]
Advances in pharmacologic stress agents: focus on regadenoson. [2010.09]
Safety of regadenoson in patients with end-stage renal disease. [2010.01.01]
Regadenoson. [2010]
Regadenoson: a new myocardial stress agent. [2009.09.22]
Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. [2009.08]
Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs. [2008.11]
Regadenoson in the detection of coronary artery disease. [2008]
Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. [2007.07]
Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. [2007.07]
Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. [2007.06]
Regadenoson (CV Therapeutics/Astellas). [2006.03]
Other possibly related research studies
Gateways to clinical trials. [2007.12]
Gateways to clinical trials. [2006.11]
Gateways to clinical trials. [2004.05]
The future of pharmacologic stress: selective A2A adenosine receptor agonists. [2004.07.22]
Gateways to clinical trials. [2003.12]
Gateways to clinical trials. [2003.05]
Current advances in vasodilator pharmacological stress perfusion imaging. [2009.05]
Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. [2009.10]
Gateways to clinical trials. [2009.07]
Targeting iNKT cells for the treatment of sickle cell disease. [2011.08]
Gateways to clinical trials. [2010.09]
|